🏢 官网IRPGENCodex · 实盘不做把握 9/10
北京时间·🕒 发布 20:00:00时区推断·⟳ 抓取 20:01:14·⚡ 决策 07-21 20:02:56 +1m42s·98.3 天前
Precigen宣布将于8月4日发布二季度业绩并召开电话会
本次公告仅预告Precigen将在2026年8月4日发布二季度业绩并提供业务更新，未披露收入、利润、指引、产品商业化数据或监管进展。
📄 原文PGEN↗ 原文
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
Skip to main navigation About Overview Mission & Vision Management Board of Directors Science Overview Therapeutic Area…
不做 Precigen（PGEN.US）
仅为业绩发布日期和电话会预告，没有业绩结果、指引、商业化数据或监管进展，无法形成正期望交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-21 · 扩散 low · price-in 风险 medium ↗
关键理由
- 本次公告仅预告Precigen将在2026年8月4日发布二季度业绩并提供业务更新，未披露收入、利润、指引、产品商业化数据或监管进展。
- 业绩发布时间安排属于日历信息，不改变公司基本面预期，也无法形成同向可执行交易。
主要风险
- 真正可交易的信息需等8月4日业绩和业务更新披露后重新评估。
- 若电话会披露PAPZIMEOS商业化收入、现金流拐点或监管进展超预期，需由新信号接手。
原文全文
展开原文 · 4,638 字
Skip to main navigation
About
Overview
Mission & Vision
Management
Board of Directors
Science
Overview
Therapeutic Areas
Therapeutic Platforms
Technology Platforms
Publications
Our Medicine
PAPZIMEOS
Pipeline
Overview
Precigen Pipeline
Expanded Access Policy
Careers
Overview
Job Postings
Postdoc Program
Benefits
Investors
Overview
Press Releases
Events & Presentations
Stock
Financials
Governance
Resources
Contact
Contact
Location
PRECIGEN Investors
Press Releases
IR Nav
Press Releases
Events & Presentations
Stock
Financials
Governance
Resources
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
Jul 21, 2026
PDF Version
GERMANTOWN, Md. , July 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release second quarter 2026 financial results and provide business updates on Tuesday, August 4, 2026 . The Company will host a conference call to discuss results that day at 4:30 PM ET .
The conference call may be accessed by dialing 1-800-836-8184 ( North America ) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call.
Event details can be found on Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations .
Precigen : Advancing Medicine with Precision ®
Precigen (Nasdaq: PGEN) is a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen , visit www.precigen.com or follow us on LinkedIn or YouTube .
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, information relating to the Company's business and business plans, the success of efforts to commercialize PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults including the revenue that the Company expects to realize from such efforts, the Company's ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS, the ability of PAPZIMEOS to treat RRP, the Company's future financial and operational results including the Company's ability to reach cash flow break-even, and the Company's ability to commence clinical studies or complete ongoing clinical studies for the Company's clinical and pre-clinical stage candidates. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.
Investor Contact:
Steven M. Harasym
Tel: +1 (202) 365-2563
investors@precigen.com
Media Contact:
Donelle M. Gregory
press@precigen.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/precigen-to-announce-second-quarter-2026-financial-results-and-provide-business-updates-on-august-4-302830158.html
SOURCE Precigen, Inc.
About
Overview
Mission & Vision
Management
Board of Directors
Science
Overview
Therapeutic Areas
Therapeutic Platforms
Technology Platforms
Publications
Our Medicine
PAPZIMEOS
Pipeline
Overview
Precigen Pipeline
Expanded Access Policy
Careers
Overview
Job Postings
Postdoc Program
Benefits
Investors
Overview
Press Releases
Events & Presentations
Stock
Financials
Governance
Resources
Contact
Contact
Location
PRECIGEN Investors
Press Releases
IR Nav
Press Releases
Events & Presentations
Stock
Financials
Governance
Resources
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
Jul 21, 2026
PDF Version
GERMANTOWN, Md. , July 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release second quarter 2026 financial results and provide business updates on Tuesday, August 4, 2026 . The Company will host a conference call to discuss results that day at 4:30 PM ET .
The conference call may be accessed by dialing 1-800-836-8184 ( North America ) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call.
Event details can be found on Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations .
Precigen : Advancing Medicine with Precision ®
Precigen (Nasdaq: PGEN) is a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen , visit www.precigen.com or follow us on LinkedIn or YouTube .
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, information relating to the Company's business and business plans, the success of efforts to commercialize PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults including the revenue that the Company expects to realize from such efforts, the Company's ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS, the ability of PAPZIMEOS to treat RRP, the Company's future financial and operational results including the Company's ability to reach cash flow break-even, and the Company's ability to commence clinical studies or complete ongoing clinical studies for the Company's clinical and pre-clinical stage candidates. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.
Investor Contact:
Steven M. Harasym
Tel: +1 (202) 365-2563
investors@precigen.com
Media Contact:
Donelle M. Gregory
press@precigen.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/precigen-to-announce-second-quarter-2026-financial-results-and-provide-business-updates-on-august-4-302830158.html
SOURCE Precigen, Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。